Learn about the amazingly diverse and exciting program for Day Two of the inaugural Innovations in NAFLD Care 2022 Workshop, with sessions on Comprehensive Care pathways, current and future pharmacotherapies, and what a future integrated treatment roadmap might look like.
The podcast ventures into the emergence of digital therapeutics with Joe Rubinsztain, CEO and Co-Founder of ChronWell, and Mark Berman, CMO of Better Therapeutics. In this final conversation, the panelists provide closing thoughts on the future of this space and how it may play out across different economic systems.
The podcast ventures into the emerging space of digital therapeutics with Joe Rubinsztain, CEO and Co-Founder of ChronWell, and Mark Berman, CMO of Better Therapeutics. The panelists consider regulatory challenges for prescribing digital therapeutics as an evidence-based treatment. Additionally, Louise Campbell introduces a free lifestyle app that she is working on that aims to improve liver health.
Joe Rubinsztain, CEO and Co-Founder of ChronWell, discusses scalable technology and the future of digital health. Within this context, the panelists consider the dynamics of insurers, providers and building an understanding around the full spectrum of disease treatment.
Naim Alkhouri shares his experience conducting a feasibility study with Better Therapeutics aimed at improving liver health through use of an app. The panelists discuss cognitive behavioral therapy, noninvasive technologies, assessing endpoints and much more.
The podcast ventures into the emerging digital therapeutics space with Joe Rubinsztain, CEO and Co-Founder of ChronWell, and Mark Berman, CMO of Better Therapeutics. In this conversation, both guests share their unique backgrounds and paths to combating Fatty Liver through technological innovation.
